C-peptide vs Lixisenatide
Head-to-head comparison of C-peptide (Connecting peptide (C-peptide)) and Lixisenatide (Exendin-4-derived GLP-1 receptor agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | C-peptide | Lixisenatide |
|---|---|---|
| Category | Pain Management | Weight Management |
| Full Name | Connecting peptide (C-peptide) | Exendin-4-derived GLP-1 receptor agonist |
| Molecular Weight | 3020.3 Da | 4858 Da |
| Half-Life | ~20-30 min | 2-4 hours |
| Amino Acids | 31 | 44 |
| Typical Dose | no approved analgesic dose|research-only | 10-20 mcg daily |
| Route | IV|subQ | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 46 | 400 |
| Research Status | Pre-clinical | Approved |
C-peptide Benefits
- ✓diabetic neuropathy research
- ✓nerve function support
- ✓possible analgesic effect
Lixisenatide Benefits
- ✓postprandial glucose control
- ✓modest weight loss
- ✓appetite reduction
- ✓short-acting option
C-peptide Dosing
0.5-1.0 mg/day in research|route varies by protocol
Lixisenatide Dosing
10 mcg SC daily for 14 days|Increase to 20 mcg daily|Inject before the first meal of the day
C-peptide Side Effects
- ⚠injection-site reactions
- ⚠unknown long-term safety
Lixisenatide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠hypoglycemia when combined with insulin
Research Overview
C-peptide
C-peptide is not an approved analgesic, but multiple studies have examined its effects on peripheral nerve blood flow and neuropathy outcomes. The strongest relevance is in diabetic neuropathic pain rather than migraine.
Lixisenatide
Lixisenatide produces small but measurable weight loss in diabetes trials while improving postprandial glucose excursions. Its shorter half-life makes it a useful reference compound for first-generation incretin mimetics.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.